Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05472259
Other study ID # NALPAC
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date May 25, 2022
Est. completion date December 31, 2027

Study information

Verified date July 2022
Source Belgian Group of Digestive Oncology
Contact Lina Dewever
Phone +32 (0) 479 36 63 82
Email lina.dewever@bgdo.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A non-comparative randomized phase 2 study, evaluating the efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for metastatic pancreatic ductal adenocarcinoma (PDAC), progressive after Gemcitabine-Abraxane or Gemcitabine monotherapy


Description:

Based on the results of previous studies, the sponsor aims to assess efficacy and safety of this triplet (irinotecan, 5FU/LV and oxaliplatin) in second-line treatment in fit patients (ECOG 0-1) metastatic PDAC. The primary objective is to assess the efficacy of NALIRINOX (= investigational arm) and NALIRI (= standard care arm) in terms of Progression-Free Survival Rate (PFSR). As secondary objectives, the following will be evaluated in both arms: - Safety/toxicity and tolerability profile according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 5. - Progression free survival (PFS) - Overall response rate and duration of response as assessed by imaging (RECIST 1.1) and tumor markers - Overall survival (OS)


Recruitment information / eligibility

Status Recruiting
Enrollment 134
Est. completion date December 31, 2027
Est. primary completion date June 30, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Histologically proven metastatic adenocarcinoma of the pancreas - Progression documented after gemcitabine-Abraxane, or gemcitabine monotherapy - Signed written informed consent - Age = 18 - ECOG PS 0/1 at study entry - Measurable disease - Adequate renal (serum creatinine = 1.5x upper reference range), liver (total bilirubin = 1.5x upper reference range) and hematopoietic functions (PMN = 1,5x109/L, platelets = 100x109/L, hemoglobin = 9g/dl) - INR/PTT = 1.5x ULN - Life expectancy of at least 12 weeks - Effective contraception for both male and female patients if the risk of conception exists during treatment and for one month after the last administration - Peripheral Neuropathy < grade 2 Exclusion Criteria: - Uncontrolled concurrent CNS, cardiac, infectious diseases, hypertension - History of myocardial infarction, deep venous or arterial thrombosis, CVA during the last 6 months - Known hypersensitivity to any of the components, including excipients, of study treatments - Previous malignancy in the last past 3 years except basal cell cancer of the skin or preinvasive cancer of the cervix or carcinoma in situ of any type - Pregnancy or breast feeding - Medical or psychological conditions that would not permit the patient to complete the study or sign inform consent - Unstable angina, congestive heart failure =NYHA class II - Uncontrolled hypertension despite optimal management (systolic blood pressure >150 mmHg or diastolic pressure > 90mmHg) - HIV infection - Complete DPD deficiency - Liver failure, cirrhosis Child Pugh B or C - Active chronic hepatitis B or C with a need for antiviral treatment - Brain metastasis - Major surgery, open biopsy or significant traumatic injury within 4 weeks prior to the first dose of treatment - History of organ allograft - Ongoing uncontrolled, serious infection - Renal failure requiring dialysis - Patients receiving or having received any investigational treatment within 4 weeks prior to study entry, or participating to another clinical study

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Nanoliposomal irinotecan
In the control arm (Naliri) a dose of 70mg/m² is administered in combination with 5FU and leucovorin In the investigational arm (Nalirinox) a dose of 50mg/m² is administered in combination with 5FU, leucovorin and oxaliplatin
5 FU
In the control arm (Naliri) a dose of 2400 mg/m² is administered in combination with nanoliposomal irinotecan and leucovorin In the investigational arm (Nalirinox) a dose of 2400 mg/m² is administered in combination with nanoliposomal irinotecan, leucovorin and oxaliplatin
Leucovorin
In the control arm (Naliri) a dose of 400 mg/m² is administered in combination with nanoliposomal irinotecan and 5FU In the investigational arm (Nalirinox) a dose of 400 mg/m² is administered in combination with nanoliposomal irinotecan, 5FU and oxaliplatin
Oxaliplatin
Only administered in the investigational arm (Nalirinox): a dose of 60 mg/m² is administered in combination with nanoliposomal irinotecan, 5FU and Leucovorin

Locations

Country Name City State
Belgium UZ Antwerpen Antwerp
Belgium AZ Imelda Bonheiden
Belgium AZ St-Lucas Brugge West-Vlaanderen
Belgium Cliniques Universitaires Saint-Luc UCL Brussels
Belgium ULB Erasme Brussels
Belgium Grand Hopital de Charleroi Charleroi
Belgium AZ Maria Middelares Ghent
Belgium University Hospital Ghent Ghent
Belgium CHC MontLégia Liège
Belgium AZ Sint-Maarten Mechelen
Belgium CHU Ambroise Paré Mons
Belgium CHR Namur Namur

Sponsors (2)

Lead Sponsor Collaborator
Belgian Group of Digestive Oncology University Hospital St Luc, Brussels

Country where clinical trial is conducted

Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Other Exploratory lab investigation for potential prognostic and predictive biomarkers on blood and tumor samples Translational research will be performed for potential prognostic and predictive biomarkers. For that purpose, plasma samples will be kept in the selected centres' biobanks.
The translational research will be carried out on tumor samples collected before the start of treatment and on blood samples collected as per below.
Tumor tissue:
10 slices of the paraffin embedded tissue collected during the diagnosis of the disease will be collected.
Blood samples:
Two 10 ml blood samples from each patient who consents to participate in the biological study will be collected before the start of the treatment, and before each cycle till the discontinuation of the treatment.
The exact measurements that will be done, have not been defined yet.
Sapmples will be collected throughout the study and shipped to the sponsor maximum 1 year after last 15 day follow-up visit
Primary Efficacy of NALIRINOX and NALIRI through Progression-Free Survival at D85 NALIRINOX is the investigational arm and NALIRI is the standard care arm. The efficacy will be assessed in terms of the Progression-Free Survival Rate (PFSR). This is defined as the proportion of patients alive and free of progression at day 85. at day 85 from randomization
Secondary Safety/toxicity and tolerability profil: Severety of adverse events Adverse events and Serious Adverse events will be assessed during the study treatment and until 14 days later. Severety will be graded according to the NCI-CTCAE version 5.0 and relationship to the study medication will be defined. until 14 days after End of Treatment
Secondary Safety/toxicity and tolerability profil: Laboratory assessments Standard laboratory safety assessments: They are mandatory prior to each administration of study medication and at the 15 days follow-up visit.
Clinically significant vs not clinically significant.
until 14 days after End of Treatment
Secondary Safety/toxicity and tolerability profil: ECOG WHO ECOG performance status (PS) will be defined prior to each administration of study medication and at the 15 days follow-up visit following the ECOG Performance Status Scale. until 14 days after End of Treatment
Secondary Safety/toxicity and tolerability profil: review of body systems A full review of body systems will be performed: heart rate, blood pressure, respiratory rate, body temperature, height, weight and ECG (screening visit only, unless clinically indicated).
Clinically significant versus not clinically significant
until 14 days after End of Treatment
Secondary Progression Free Survival and sensitivity analysis: Effect of Center on prognostic factors The effect of potential prognostic factors will be assessed through sensitivity analyses, including:
Investigational Center
From date of first study treatment administration until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years after End of Treatment.
Secondary Progression Free Survival and sensitivity analysis: Effect of tumor location on prognostic factors The effect of potential prognostic factors will be assessed through sensitivity analyses, including:
Location of tumor (head of the pancreas versus other location)
From date of first study treatment administration until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years after End of Treatment
Secondary Progression Free Survival and sensitivity analysis: Effect of previous chemotherapy on prognostic factors The effect of potential prognostic factors will be assessed through sensitivity analyses, including:
Previous chemotherapy: gemcitabine alone vs gem-abx
From date of first study treatment administration until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years after End of Treatment
Secondary Progression Free Survival and sensitivity analysis: effect of ECOG on prognostic factors The effect of potential prognostic factors will be assessed through sensitivity analyses, including:
WHO ECOG performance status (0 versus 1)
From date of first study treatment administration until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years after End of Treatment
Secondary Objective tumor response: Rate of complete response and partial response Tumor (response) evaluation will be performed according to RECIST criteria v. 1.1 (CT scan thorax, abdomen and pelvis or MRI abdomen and pelvis + CT chest) based upon the investigator's assessment. Overall response is defined as a best response of either CR or PR (CR+PR). performed within 28 days before start therapy, 3 times every 6 weeks and afterwards every 8 weeks
Secondary Duration of overall survival For patients who are still alive at the time of study analysis or who are lost to follow up, survival will be censored at the last recorded date that the patient is known to be alive or at the date of data cut-off, whatever occurs earlier. Time from Day 1 of therapy to death until maximum 5 years after End of Treatment
Secondary Duration of disease control Disease control is defined as a best response of either CR, PR, or SD (CR+PR+SD). From date of first study treatment administration until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years after End of Treatment
Secondary Duration of response The duration of response will be censored on the date of last known tumor assessment for not progressed patients lost to follow up or deceased prior to the next planned tumor assessment (within 60 days). Not evaluable patients at one time point assessment will be censored at the date of last known assessment. Time from measurement criteria are first met for CR/PR to either the first time disease progression is documented or death (for not progressed patients who deceased within 60 days from last tumor assessment) until maximum 5 years after EOT
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04935359 - Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2 Phase 3
Active, not recruiting NCT05095064 - Retrospective Study on the Efficacy and Tolerability of Liposomal Irinotecan
Active, not recruiting NCT05039177 - A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies Phase 1/Phase 2
Recruiting NCT04888312 - Safety and Efficacy of Mitazalimab in Combination With Chemotherapy in Pancreatic Cancer Patients Phase 1/Phase 2
Terminated NCT04390763 - Study of Efficacy and Safety of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) Phase 2
Not yet recruiting NCT06206876 - FL118 for Treating Patients With Advanced Pancreatic Ductal Adenocarcinoma Phase 1
Recruiting NCT05642962 - Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC) Phase 1/Phase 2
Completed NCT02501902 - Dose-Escalation Study Of Palbociclib + Nab-Paclitaxel In mPDAC Phase 1
Active, not recruiting NCT04581343 - A Phase 1B Study of Canakinumab, Spartalizumab, Nab-paclitaxel, and Gemcitabine in Metastatic PC Patients Phase 1
Completed NCT02558894 - Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma Phase 2
Terminated NCT02732938 - Ph1b/2 Study of PF-04136309 in Combination With Gem/Nab-P in First-line Metastatic Pancreatic Patients Phase 2
Recruiting NCT06445062 - Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors Phase 1/Phase 2
Recruiting NCT02600949 - Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer Phase 1
Recruiting NCT05630183 - A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer Phase 2
Completed NCT02583477 - Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma Phase 1/Phase 2
Terminated NCT04329949 - Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Phase 3
Terminated NCT02101021 - Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Participants With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma Phase 3
Suspended NCT05685602 - CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer Phase 1
Not yet recruiting NCT06398587 - Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma Phase 2
Completed NCT04990037 - A Study of the Safety and Tolerance of CAN04 in Combination With FOLFIRINOX in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma Phase 1